

# Bristol CCG Don't Wait to Anticoagulate Project

Sarah White – Quality Improvement Lead West of England Academic Health Science Network



### Why Quality Improvement?



### Method or Model?

An approach to personal or organisational learning, development and improvement






### What is Quality?




In healthcare the definitions for quality are universally accepted as:

- Safe
- Timely
- Effective
- Efficient
- Equitable
- Person- Centred



- Avoiding needless deaths
- Avoiding needed pain
- Eliminating wastes
- Eliminating unwanted waits
- Eliminating patient and carers feeling helpless
- Consistently for everyone every time



### What is Quality Improvement?



### Systematic Approach using specific techniques

- A cycle of improvement which involves data collection, problem definition and diagnosis, testing and subsequent implementation the changes.
- A set of tools and techniques that support individuals to implement improvements.
- A recognition of the importance of engaging stakeholders in the improvement of the service.
- A recognition of the importance of culture and the need for clinical and management leadership.



### Why Quality Improvement?



- Focus on outcomes
- Flattening hierarchies
- Giving everyone a voice
- Bringing staff and service users together to improve and redesign the way that care is provided

# What is Don't Wait to Anticoagulte?



WEAHSN Project working with Industry Partners

Phase 1 – 11 Innovator Practices – co design and

test of theory

Phase 2 – Gloucestershire CCG

Good outcomes

Phase 1 – 8% increase in Anticoagulation rates

Legacy of QI learning

National roll-out



#### What have we learnt?



Lead GP is very influential Clinical skills update is essential High workload is seen as a factor Role of MOPs essential QI is seen as a positive mechanism for change QI leaves a legacy Partnership between GP and MOPs is key to successful outcome Website seen as a useful tool



### **Phase 2 Results Table**




	Before	After	Difference	Percentage change
AF patients on antiplatelets only	1027	887	-140	-13.6%
AF patients on sub- optimal warfarin	896	778	-118	-13.2%
AF patients on no treatment	1225	1248	23	1.9%



### QI in DWAC The Improvement Journey





Optimising Anticoagulation in AF patients

Increase in optimally managed AF patients

What changes can we make?

### **AF Pathway in Primary Care**



What is the current review process?

How will you stratify the patient list?

What happens with poorly managed Warfarin patients?

Are non compliant patients routinely offered a NOAC?

Does the patient have an understanding of risk?

Do you hold anticoagulation clinics?

Are elderly and frail patients considered for anticoagulation?


What is the patient recall process?

Is the AF pathway clearly articulated within the practice?

Do all GP's offer the same opportunities for patient discussion?

### **Using the Tools**





www.dontwaittoanticoagulate.com



## Resources Available on the Website



- All current anticoagulation drug information that can be compared side by side
- Patient Risk sheets
- FAQs
- Project Tools such as
  - Project Poster
  - Project Summary Document
  - OPRA
  - New Medicines Service



